Abstract:AIM:To examine the effect of celecoxib on tumor growth and angiogenesis in an orthotopic implantation tumor model of colon cancer.METHODS:Human colorectal adenocarcinoma HT-29 cells were implanted subcutaneously in nude mice. Four groups of animals received different doses of celecoxib after tumor implantation. After 42 days, all animals were evaluated for changes in body weight, the volume and weight of colorectal tumors, and tumor growth inhibition. The content of prostaglandin E(2) (PGE(2)) in the tumor tissue homogenate was estimated by radioimmunoassay (RIA). Cyclooxygenase-2 (COX-2) and CD34 expression in tumor tissue was assessed by immunohistochemistry, and the microvessel density (MVD) of tumor tissue was determined. Apoptosis of the tumor cells was detected by the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL). The expression of vascular endothelial growth factor (VEGF) mRNA and matrix metalloproteinase-2 (MMP-2) mRNA extracted from the tumor tissue was analyzed by reverse transcriptase polymerase chain reaction (RT-PCR).RESULTS:There was no statistically significant change in the animals' body weight between the treatment groups. However, with increasing doses of celecoxib, the volume and weight of the tumor decreased. The rates of tumor growth inhibition for the L (low), M (medium) and H (high) groups were 25.30%, 38.80%, and 76.92%, respectively, which were significant compared to the C (control) group. There were significant differences in COX-2 expression in the tumor tissue between all groups, except between the L and M groups. Celecoxib exposure also reduced PGE2 levels in the tumor tissue homogenates. The level of PGE(2) correlated to the weight of tumor (r=0.8814, P < 0.05) and to COX-2 expression (r=0.8249, Puse < 0.05). Compared to the control group, the tumor cells from celecoxib-treated mice had a significantly higher apoptotic index. Celecoxib also decreased CD34(+) expression in tumors from treated mice. There were significant differences in the MVD between all groups except between groups H and M. Celecoxib significantly reduced the expression of VEGF and MMP-2 mRNA in the group H but not in L and M groups. The MVD in tumor tissue was closely related to the PGE2 levels, as well as the expression of VEGF and MMP-2 mRNA (r = 0.9006, r = 0.8573 and r = 0.6427, respectively; P < 0.05).CONCLUSIONS:By inhibiting COX-2, PGE(2) synthesis, and VEGF and MMP-2 mRNA expression in tumor tissue, celecoxib enhances tumor cell apoptosis, thereby inhibiting the growth and angiogenesis of orthotopically implanted tumors in a mouse model of human colorectal cancer.

Cyclooxygenase-2 Induces Angiogenesis in Pancreatic Cancer Mediated by Prostaglandin E-2

[Effect of Selective Cyclooxygenase-2 Inhibitor Celebrex on Expression of Vascular Endothelial Growth Factor (VEGF) in Pancreatic Carcinoma].

Impact of the Selective Cyclooxygenase-2 Inhibitor Celebrex on Angiogenesis in Pancreatic Carcinoma

Effects of Selective Cyclooxygenase-2 Inibitor Celebrex on the Expression of VEGF in Pancreatic Carcinoma PC-3 Cell Lines

Vascular endothelial growth factor and not cyclooxygenase 2 promotes endothelial cell viability in the pancreatic tumor microenvironment

Selective Inhibition of Cyclooxygenase-2 Suppresses the Growth of Pancreatic Cancer Cells in Vitro and in Vivo

Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer

Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity.

Celecoxib Inhibits Vascular Endothelial Growth Factor Expression in and Reduces Angiogenesis and Metastasis of Human Pancreatic Cancer Via Suppression of Sp1 Transcription Factor Activity

Cyclooxygenase-2 Expression Is Up-Regulated In Human Pancreatic Cancer

Elevated COX-2 Expression Promotes Angiogenesis Through EGFR/p38-MAPK/Sp1-Dependent Signalling in Pancreatic Cancer

Cyclooxygenase-2 Promotes Angiogenesis by Increasing Vascular Endothelial Growth Factor and Predicts Prognosis in Gallbladder Carcinoma

COX-2 expression and tumor angiogenesis in colorectal cancer.

Therapeutic Effects of COX-2 Inhibitor Celecoxib on Nude Mice Bearing Human Pancreatic Cancer Xenograft

Celecoxib Inhibits Tumor Growth and Angiogenesis in an Orthotopic Implantation Tumor Model of Human Colon Cancer.

Celecoxib Suppresses Fibroblast Growth Factor-2 Expression in Pancreatic Ductal Adenocarcinoma PANC-1 Cells.

Assessment of celecoxib pharmacodynamics in pancreatic cancer

[Effects of Rofecoxib on Angiogenesis of Pancreatic Cancer Xenograft in Nude Mice].

Cyclooxygenase-2 Expression and Angiogenesis in Colorectal Cancer

Cyclooxygenase-2 expression correlates with angiogenesis and vascular endothelial growth factor-A in non-small cell lung cancer

Effects of Cyclooxygenase-2 in Tumor Invasion and Metastasis and Treatment